Friday, July 18, 2025 7/18/2025

Supplement to cover cost of participation in BIO Innovation Zone Exhibit

Award Number: R44HL103006
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/06/2010
PERIOD OF PERFORMANCE END DATE: 11/30/2015

Group Awards By:

View Award Description

Supplement to cover cost of participation in BIO Innovation Zone Exhibit - DESCRIPTION (provided by applicant): Bacterial contamination of platelets is considered the greatest infectious risk of blood product transfusion today at about 1 in 2000 platelet units, which is several orders of magnitude greater than that of HIV. Bacterial contamination at high levels can lead to severe morbidity or mortality in transfusion recipients. The American Association of Blood Banks issued directives in 2004 and 2011 requiring bacterial testing on all platelet units. Two recent studies have demonstrated that current FDA-approved culture-based methods that test for contamination 1 to 4 days prior to transfusion miss a majority of contaminated units. The time elapsed between sampling and actual transfusion and the associated risk of bacterial contamination is a fundamental problem that cannot be addressed by current culture-based platelet testing. A rapid and sensitive point-of-issue test for bacterial contamination would overcome this problem by providing an assessment of potential contamination immediately prior to transfusion. Such a test would be used by a hospital laboratory close to the point of transfusion or by a transfusion center preparing to ship platelet units to a clinical center. A rapid test would ideally require less than 15 min, have detection sensitivity of 104 CFU/mL or better, be fully automated, and be comparable in cost to current tests. BacTx technology, developed by Immunetics for detection of bacterial contamination in platelets, employs a unique and innovative assay chemistry capable of rapidly detecting both Gram-positive and Gram-negative bacteria in platelet units. The first-generation BacTx Bacterial Detection Kit recently received clearance from FDA (CBER) as a quality control test for pooled, leukocyte-reduced whole blood derived platelets, but this test is not ideally suited for use as a point of issue test due to its length (45 min) and complexity (requiring centrifugation and accurate pipetting). In the Phase I project, we successfully demonstrated feasibility of a simple, filter-based BacTx assay which is rapid (<15 min) and highly amenable to automation, while maintaining the high sensitivity and specificity of the original BacTx test. In Phase II, we will optimize and configure the rapid test for automated performance and will design, build and evaluate prototype instruments and software to run the test. The instrument and software development will be carried out in collaboration with engineering partners who have many years of experience in the development of medical test systems with comparable functionality. At the conclusion of Phase II, we will have developed and validated an integrated rapid BacTx test system ready for clinical studies aimed at 510(k) approval. Commercialization of this rapid test will enable a paradigm shift in platelet testing and a significant reduction in the number of bacterially contaminated platelet units transfused into critically ill patients. Furthermore, adopton of the rapid BacTx test could ultimately lead to a change in policy regarding platelets, significantly reducing costs for blood banks by allowing an extension of the storage life of platelet units from 5 to 7 days.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2021 ( Subtotal = -$91,111 )
2021	2015	IMMUNETICS, INC.	27 DRYDOCK AVE STE 12	BOSTON	MA	02210	SUFFOLK	USA	Blood Diseases and Resources Research	001	4	10/1/2020	SUPPLEMENT FOR EXPANSION	-$91,111
2021	2015	IMMUNETICS, INC.	27 DRYDOCK AVE STE 12	BOSTON	MA	02210	SUFFOLK	USA	Blood Diseases and Resources Research	000	4	10/1/2020	SUPPLEMENT FOR EXPANSION	-$418
2021	2015	IMMUNETICS, INC.	27 DRYDOCK AVE STE 12	BOSTON	MA	02210	SUFFOLK	USA	Blood Diseases and Resources Research	004	4	10/3/2020	SUPPLEMENT FOR EXPANSION	-$91,111
2021	2015	IMMUNETICS, INC.	27 DRYDOCK AVE STE 12	BOSTON	MA	02210	SUFFOLK	USA	Blood Diseases and Resources Research	002	4	10/3/2020	SUPPLEMENT FOR EXPANSION	$418
2021	2015	IMMUNETICS, INC.	27 DRYDOCK AVE STE 12	BOSTON	MA	02210	SUFFOLK	USA	Blood Diseases and Resources Research	003	4	10/3/2020	SUPPLEMENT FOR EXPANSION	$91,111
														Subtotal = -$91,111

Issue Date FY: 2018 ( Subtotal = -$463 )
2018	2016	IMMUNETICS, INC.	27 DRYDOCK AVE STE 12	BOSTON	MA	02210	SUFFOLK	USA	Blood Diseases and Resources Research	001	5	6/25/2018	EXTENSION WITH OR WITHOUT FUNDS	$0
2018	2015	IMMUNETICS, INC.	27 DRYDOCK AVE STE 12	BOSTON	MA	02210	SUFFOLK	USA	Blood Diseases and Resources Research	000	4	3/6/2018	NON-COMPETING CONTINUATION	$0
2018	2015	IMMUNETICS, INC.	27 DRYDOCK AVE STE 12	BOSTON	MA	02210	SUFFOLK	USA	Blood Diseases and Resources Research	002	4	9/17/2018	SUPPLEMENT FOR EXPANSION	-$463
														Subtotal = -$463

Issue Date FY: 2016 ( Subtotal = $972,241 )
2016	2016	IMMUNETICS, INC	27 DRYDOCK AVE	BOSTON	MA	02210	SUFFOLK	USA	Blood Diseases and Resources Research	000	5	11/24/2015	EXTENSION WITH OR WITHOUT FUNDS	$972,241
														Subtotal = $972,241

Issue Date FY: 2015 ( Subtotal = $994,098 )
2015	2015	IMMUNETICS, INC	27 DRYDOCK AVE	BOSTON	MA	02210	SUFFOLK	USA	Blood Diseases and Resources Research	002	4	7/24/2015	SUPPLEMENT FOR EXPANSION	$5,000
2015	2015	IMMUNETICS, INC	27 DRYDOCK AVE	BOSTON	MA	02210	SUFFOLK	USA	Blood Diseases and Resources Research	001	4	2/20/2015	NON-COMPETING CONTINUATION	$98,910
2015	2015	IMMUNETICS, INC	27 DRYDOCK AVE	BOSTON	MA	02210	SUFFOLK	USA	Blood Diseases and Resources Research	000	4	11/10/2014	NON-COMPETING CONTINUATION	$890,188
														Subtotal = $994,098

Issue Date FY: 2014 ( Subtotal = $0 )
2014	2013	IMMUNETICS, INC	27 DRYDOCK AVE	BOSTON	MA	02210	SUFFOLK	USA	Blood Diseases and Resources Research	000	3	7/16/2014	COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2013 ( Subtotal = $999,842 )
2013	2013	IMMUNETICS, INC	27 DRYDOCK AVE	BOSTON	MA	02210	SUFFOLK	USA	Blood Diseases and Resources Research	000	3	7/12/2013	COMPETING CONTINUATION	$999,842
														Subtotal = $999,842

Grand Total All Awards = $2,874,607

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Supplement to cover cost of participation in BIO Innovation Zone Exhibit

Award Number: R44HL103006

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/06/2010

PERIOD OF PERFORMANCE END DATE: 11/30/2015

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer